How Austedo’s VMAT2 inhibition reshapes tardive dyskinesia care, while real-world data reveal underdiagnosis, low uptake, and new studies ahead.
Verena Ramirez-Campos, MD
Advertisement
Articles by Verena Ramirez-Campos, MD
Three new Teva posters show Austedo sustains tardive dyskinesia improvement long term, works in real-world care, and education boosts diagnosis and visits.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs
2
New in Narcolepsy: Pharmacology Updates
3
New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD
4
Morning Rounds: News From August 3-9
5